Quarterly Report Q3 2016

April 16, 2018

Prometic reports third quarter 2016 highlights and financial results

  • Acquisition of Telesta Therapeutics adds $37.4 million in cash and short-term investments to $39.0 million balance reported at end of Q3
  •  Investment in commercial & manufacturing infrastructure ahead of plasminogen commercial launch included in R&D expense
  •  Plasminogen pivotal clinical trial results performed at 100% response rate meeting primary and secondary end points in plasminogen deficient patients
  •  Primary and secondary endpoints met in clinical trials in metabolic syndrome patients
  •  2016 YTD revenues of $12.3 million vs. $10.5 million for same 2015 period
Previous Flipbook
Management Circular 2016
Management Circular 2016

Notice is hereby given that the Annual and Special Meeting of Shareholders (the "Meeting") of Prometic Life...

Next Flipbook
Quarterly Report Q2 2016
Quarterly Report Q2 2016

Prometic reports second quarter 2016 highlights and financial results